Hyperprolactinemia

Journal of Human Reproductive Sciences

Volumn 6, Issue 3, 2013, Pages 168-175

  Majumdar, Abha ^a   Mangal, Nisha Sharma ^a  

^a SIR GANGA RAM HOSPITAL   (India)

Author keywords

Anovulation; galactorrhea; hyperprolactinemia; prolactin; prolactinomas

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; BROMOCRIPTINE; CABERGOLINE; DEPOT PLUS BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; EPIDERMAL GROWTH FACTOR; ESTROGEN; GONADORELIN; HISTAMINE; HYPOTHALAMUS HORMONE; KISSPEPTIN; LISURIDE; METERGOLINE; NORADRENALIN; PERGOLIDE; PRASTERONE SULFATE; PROGESTERONE; PROLACTIN; PROTIRELIN; QUINAGOLIDE; SEROTONIN; SEX HORMONE BINDING GLOBULIN; SOMATOSTATIN; TERGURIDE; TESTOSTERONE; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ACNE; AMENORRHEA; AUDITORY HALLUCINATION; BONE DENSITY; BONE MASS; CHRONIC KIDNEY FAILURE; CONSTIPATION; CRANIOPHARYNGIOMA; DELUSION; DEPRESSION; DIZZINESS; DOPAMINERGIC SYSTEM; ERECTILE DYSFUNCTION; ESTROGEN BLOOD LEVEL; ESTROGEN DEFICIENCY; FAINTNESS; FAMILY PLANNING; FIRST PASS EFFECT; GALACTORRHEA; GONAD FUNCTION; GYNECOMASTIA; HEADACHE; HIRSUTISM; HORMONE SUBSTITUTION; HUMAN; HYPERPROLACTINEMIA; HYPOGONADOTROPIC HYPOGONADISM; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; HYPOTHALAMUS; HYPOTHALAMUS HYPOPHYSIS SYSTEM; HYPOTHYROIDISM; IMMUNE RESPONSE; INFERTILITY; LACTATION; LIBIDO DISORDER; LUTEINIZING HORMONE RELEASE; MOOD CHANGE; NAUSEA; NOSE OBSTRUCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGOMENORRHEA; ORTHOSTATIC HYPOTENSION; OSTEOPOROSIS; OVARY INSUFFICIENCY; OVARY POLYCYSTIC DISEASE; PITUITARY STALK; POSTMENOPAUSE; PREGNANCY; PREVALENCE; PROGESTERONE BLOOD LEVEL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; PROLACTIN SECRETING CELL; PROLACTINOMA; RADIOIMMUNOASSAY; REVIEW; SECONDARY AMENORRHEA; SECRETION (PROCESS); SIDE EFFECT; TRANSSPHENOIDAL HYPOPHYSECTOMY; VASOSPASM; VOMITING;

EID: 84890013398     PISSN: 09741208     EISSN: 19984766     Source Type: Journal    
DOI: 10.4103/0974-1208.121400     Document Type: Review

References (46)

1. Biller BM, Luciano A, Crosignani PG, Molitch M, Olive D, Rebar R, et al. Guidelines for the diagnosis and treatment of hyperprolactinemia. J Reprod Med 1999;44(Suppl 12):1075-84.
2. Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: Structure, function, and regulation of secretion. Physiol Rev 2000;80:1523-631.
3. Gibney J, Smith TP, McKenna TJ. The impact on clinical practice of routine screening for macroprolactin. J Clin Endocrinol Metab 2005;90:3927-32.
4. Donadio F, Barbieri A, Angioni R, Mantovani G, Beck-Peccoz P, Spada A, et al. Patients with macroprolactinaemia: Clinical and radiological features. Eur J Clin Invest 2007;37:552-7.
5. McKenna TJ. Should macroprolactin be measured in all hyperprolactinaemic sera? Clin Endocrinol (Oxf) 2009;71:466-9.
6. Chahal J, Schlechte J. Hyperprolactinemia. Pituitary 2008;11:141-6.
7. Glezer A, Soares CR, Vieira JG, Giannella-Neto D, Ribela MT, Goffin V, et al. Human macroprolactin displays low biological activity via its homologous receptor in a new sensitive bioassay. J Clin Endocrinol Metab 2006;91:1048-55.
8. Benker G, Jaspers C, Häusler G, Reinwein D. Control of prolactin secretion. Klin Wochenschr 1990;68:1157-67.
9. Halbreich U, Kinon BJ, Gilmore JA, Kahn LS. Elevated prolactin levels in patients with schizophrenia: Mechanisms and related adverse effects. Psychoneuroendocrinol 2003;28 (Suppl 1):53-67.
10. Nilsson LA, Roepstorff C, Kiens B, Billig H, Ling C. Prolactin suppresses malonyl-CoA concentration in human adipose tissue. Horm Metab Res 2009;41:747-51.
11. Huang I, Gibson M, Peterson CM. Endocrine disorders. In: Berek JS. editor. Berek and Novak's Gynecology, 14th ed. Philadelphia: Lippincott Williams and Wilkins; 2007. p. 1069-136.
12. Webster J, Scanlon MF. Prolactinomas. In: Sheaves R, Jenkins PJ, Wass JA, editors. Clinical Endocrine Oncology. Oxford: Blackwell Science; 1997. p. 189-94.
13. Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992;13:220-40.
14. Kleinberg DL, Noel GL, Frantz AG. Galactorrhea: A study of 235 cases, including 48 with pituitary tumors. N Engl J Med 1977;296:589-600.
15. Tolis G, Somma M, Van Campenhout J, Friesen H. Prolactin secretion in sixty-five patients with galactorrhea. Am J Obstet Gynecol 1974;118:91-101.
16. Boyd AE 3rd, Reichlin S, Turksoy RN. Galactorrhea-amenorrhea syndrome: Diagnosis and therapy. Ann Intern Med 1977;87:165-75.
17. Minakami H, Abe N, Oka N, Kimura K, Tamura T, Tamada T. Prolactin release inpolycystic ovarian syndrome. Endocrinol Jpn 1988;35:303-10.
18. Klibanski A, Neer RM, Beitins IZ, Ridgway EC, Zervas NT, McArthur JW. Decreased bone density in hyperprolactinemic women. N Engl J Med 1980;303:1511-4.
19. Schlechte J, el-Khoury G, Kathol M, Walkner L. Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 1987;64:1021-6.
20. Biller BM, Baum HB, Rosenthal DI, Saxe VC, Charpie PM, Klibanski A. Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 1992;75:692-7.
21. Klibanski A, Biller BM, Rosenthal DI, Schoenfeld DA, Saxe V. Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab 1988;67:124-30.
22. Biller BM. Hyperprolactinemia. Int J Fertil Womens Med 1999;44:74-7.
23. Luciano AA. Clinical presentation of hyperprolactinemia. J Reprod Med 1999;44 (Suppl 12):1085-90.
24. Melmed S, Jameson JL. Disorders of the anterior pituitary and hypothalamus. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison's Principles of Internal Medicine, 16th ed. New York: McGraw Hill; 2008. p. 2076-97.
25. Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O. Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma. Clin Endocrinol (Oxf) 2010;73:502-7.
26. Kearns AE, Goff DC, Hayden DL, Daniels GH. Risperidone-associated hyperprolactinemia. Endocr Pract 2000;6:425-9.
27. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Endocrine Society. Diagnosis and treatment of hyperprolactinemia: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011;96:273-88.
28. Schlechte JA. Long-term management of prolactinomas. J Clin Endocrinol Metab 2007;92:2861-5.
29. Turner TH, Cookson JC, Wass JA, Drury PL, Price PA, Besser GM. Psychotic reactions during treatment of pituitary tumours with dopamine agonists. Br Med J (Clin Res Ed) 1984;289:1101-3.
30. Motazedian S, Babakhani L, Fereshtehnejad SM, Mojthahedi K. A comparison of bromocriptine and cabergoline on fertility outcome of hyperprolactinemic infertile women undergoing intrauterine insemination. Indian J Med Res 2010;131:670-4.
31. Bahceci M, Sismanoglu A, Ulug U. Comparison of cabergoline and bromocriptine in patients with asymptomatic incidental hyperprolactinemia undergoing ICSI-ET. Gynecol Endocrinol 2010;26:505-8.
32. Horvath J, Fross RD, Kleiner-Fisman G, Lerch R, Stalder H, Liaudat S, et al. Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists. Mov Disord 2004;19:656-62.
33. Rascol O, Pathak A, Bagheri H, Montastruc JL. New concerns about old drugs: Valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance. Mov Disord 2004;19:611-3.
34. Vance ML, Evans WS, Thorner MO. Drugs five years later. Bromocriptine. Ann Intern Med 1984;100:78-91.
35. Katz E, Weiss BE, Hassell A, Schran HF, Adashi EY. Increased circulating levels of bromocriptine after vaginal compared with oral administration. Fertil Steril 1991;55:882-4.
36. Merola B, Colao A, Caruso E, Sarnacchiaro F, Briganti F, Lancranjan I, et al. Oral and injectable long-lasting bromocriptine preparations in hyperprolactinemia: Comparison of their prolactin lowering activity, tolerability and safety. Gynecol Endocrinol 1991;5:267-76.
37. Brue T, Lancranjan I, Louvet JP, Dewailly D, Roger P, Jaquet P. A long-acting repeatable form of bromocriptine as long-term treatment of prolactin-secreting macroadenomas: A multicenter study. Fertil Steril 1992;57:74-80.
38. Passos VQ, Souza JJ, Musolino NR, Bronstein MD. Long-term follow-up of prolactinomas: Normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab 2002;87:3578-82.
39. Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: Prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 2001;86:5256-61.
40. Motta T, de Vincentiis S, Marchini M, Colombo N, D'Alberton A. Vaginal cabergoline in the treatment of hyperprolactinemic patients intolerant to oral dopaminergics. Fertil Steril 1996;65:440-2.
41. George JT, Veldhuis JD, Roseweir AK, Newton CL, Faccenda E, Millar RP, et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab 2011;96:E1228-36.
42. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006;27:485-534.
43. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006;65:265-73.
44. Essaïs O, Bouguerra R, Hamzaoui J, Marrakchi Z, Hadjri S, Chamakhi S, et al. Efficacy and safety of bromocriptine in the treatment of macroprolactinomas. Ann Endocrinol (Paris) 2002;63:524-31.
45. Herman V, Fagin J, Gonsky R, Kovacs K, Melmed S. Clonal origin of pituitary adenomas. J Clin Endocrinol Metab 1990;71:1427-33.
46. Tsagarakis S, Grossman A, Plowman PN, Jones AE, Touzel R, Rees LH, et al. Megavoltage pituitary irradiation in the management of prolactinomas: Long-term follow-up. Clin Endocrinol (Oxf) 1991;34:399-406.